- Home
- UFCS vs PLRX Comparison
UFCS vs PLRX Comparison
Compare UFCS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | PLRX |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 73.7M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UFCS | PLRX |
|---|---|---|
| Price | $53.05 | $1.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $40.50 | $2.67 |
| AVG Volume (30 Days) | 110.8K | ★ 425.7K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 87.45 | 29.97 |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $1,386,412,000.00 | N/A |
| Revenue This Year | $11.80 | N/A |
| Revenue Next Year | $8.77 | N/A |
| P/E Ratio | $22.44 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $29.75 | $1.02 |
| 52 Week High | $56.74 | $1.95 |
Technical Indicators
Market Signals| Indicator | UFCS | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 55.08 |
| Support Level | $52.01 | $1.12 |
| Resistance Level | $55.12 | $1.26 |
| Average True Range (ATR) | 1.36 | 0.05 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 17.34 | 57.87 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.